PE20120205A1 - Combinaciones antitumorales que contienen anticuerpos que reconocen especificamente cd38 y citarabina - Google Patents

Combinaciones antitumorales que contienen anticuerpos que reconocen especificamente cd38 y citarabina

Info

Publication number
PE20120205A1
PE20120205A1 PE2011001097A PE2011001097A PE20120205A1 PE 20120205 A1 PE20120205 A1 PE 20120205A1 PE 2011001097 A PE2011001097 A PE 2011001097A PE 2011001097 A PE2011001097 A PE 2011001097A PE 20120205 A1 PE20120205 A1 PE 20120205A1
Authority
PE
Peru
Prior art keywords
citarabin
specifically recognize
containing antibodies
combinations containing
tumor
Prior art date
Application number
PE2011001097A
Other languages
English (en)
Inventor
Pascale Lejeune
Patricia Vrignaud
Original Assignee
Sanofi Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=40627502&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PE20120205(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Sanofi Sa filed Critical Sanofi Sa
Publication of PE20120205A1 publication Critical patent/PE20120205A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/475—Quinolines; Isoquinolines having an indole ring, e.g. yohimbine, reserpine, strychnine, vinblastine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/10—Peptides having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Saccharide Compounds (AREA)

Abstract

REFERIDA A UNA COMBINACION FARMACEUTICA QUE COMPRENDE: A) UN ANTICUERPO HUMANIZADO QUE RECONOCE LA CD38 QUE COMPRENDE UNA CADENA PESADA CON UNA SECUENCIA DE AMINOACIDOS REPRESENTADA POR SEC ID NO: 66 Y UNA CADENA LIGERA SELECCIONADA DE SEQ ID NO: 62 Y 64 Y; B) CITARABINA. DICHA COMPOSICION ES UTIL EN EL TRATAMIENTO DE CANCER
PE2011001097A 2008-11-28 2009-11-27 Combinaciones antitumorales que contienen anticuerpos que reconocen especificamente cd38 y citarabina PE20120205A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP08291118A EP2191842A1 (en) 2008-11-28 2008-11-28 Antitumor combinations containing antibodies recognizing specifically CD38 and cytarabine

Publications (1)

Publication Number Publication Date
PE20120205A1 true PE20120205A1 (es) 2012-03-03

Family

ID=40627502

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2011001097A PE20120205A1 (es) 2008-11-28 2009-11-27 Combinaciones antitumorales que contienen anticuerpos que reconocen especificamente cd38 y citarabina

Country Status (38)

Country Link
US (1) US20120093806A1 (es)
EP (2) EP2191842A1 (es)
JP (2) JP2012510463A (es)
KR (1) KR101715958B1 (es)
CN (2) CN107096022A (es)
AR (1) AR073425A1 (es)
AU (1) AU2009321251B2 (es)
BR (1) BRPI0921858B1 (es)
CA (1) CA2745005C (es)
CL (1) CL2011001232A1 (es)
CO (1) CO6440556A2 (es)
CR (1) CR20110282A (es)
DK (1) DK2370096T5 (es)
EA (1) EA027070B1 (es)
EC (1) ECSP11011071A (es)
ES (1) ES2638926T3 (es)
HN (1) HN2011001423A (es)
HR (1) HRP20171301T1 (es)
HU (1) HUE035910T2 (es)
IL (2) IL213118A (es)
LT (1) LT2370096T (es)
MA (1) MA32899B1 (es)
MX (1) MX344973B (es)
NI (1) NI201100107A (es)
NZ (1) NZ593085A (es)
PA (1) PA8849901A1 (es)
PE (1) PE20120205A1 (es)
PL (1) PL2370096T3 (es)
PT (1) PT2370096T (es)
RS (1) RS56248B1 (es)
SG (1) SG171821A1 (es)
SI (1) SI2370096T1 (es)
TN (1) TN2011000242A1 (es)
TW (1) TWI436770B (es)
UA (1) UA104160C2 (es)
UY (1) UY32266A (es)
WO (1) WO2010061359A1 (es)
ZA (1) ZA201104064B (es)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2191842A1 (en) * 2008-11-28 2010-06-02 Sanofi-Aventis Antitumor combinations containing antibodies recognizing specifically CD38 and cytarabine
BR112013006769B1 (pt) 2010-09-27 2021-02-02 Morphosys Ag combinação sinérgica
UA112170C2 (uk) * 2010-12-10 2016-08-10 Санофі Протипухлинна комбінація, що містить антитіло, яке специфічно розпізнає cd38, і бортезоміб
JOP20210044A1 (ar) 2010-12-30 2017-06-16 Takeda Pharmaceuticals Co الأجسام المضادة لـ cd38
LT2900232T (lt) 2012-09-25 2018-02-26 Morphosys Ag Deriniai ir jų panaudojimas
CN105407921A (zh) * 2013-03-13 2016-03-16 赛诺菲 包含抗cd38抗体和卡非佐米的组合物
TW201522378A (zh) 2013-10-31 2015-06-16 Sanofi Sa 用於治療人類癌症的特異性抗ｃｄ３８抗體
US9732154B2 (en) 2014-02-28 2017-08-15 Janssen Biotech, Inc. Anti-CD38 antibodies for treatment of acute lymphoblastic leukemia
US9603927B2 (en) 2014-02-28 2017-03-28 Janssen Biotech, Inc. Combination therapies with anti-CD38 antibodies
SG11201701867SA (en) 2014-09-09 2017-04-27 Janssen Biotech Inc Combination therapies with anti-cd38 antibodies
IL307913A (en) 2014-12-04 2023-12-01 Janssen Biotech Inc Anti-CD38 antibodies for the treatment of acute myeloid leukemia
BR112017024877A2 (pt) 2015-05-20 2019-09-17 Janssen Biotech, Inc. anticorpo anti-cd38 e seu uso no tratamento de amiloidose de cadeia leve e outras malignidades hematológicas positivas para cd38
WO2016209921A1 (en) 2015-06-22 2016-12-29 Janssen Biotech, Inc. Combination therapies for heme malignancies with anti-cd38 antibodies and survivin inhibitors
US20170044265A1 (en) 2015-06-24 2017-02-16 Janssen Biotech, Inc. Immune Modulation and Treatment of Solid Tumors with Antibodies that Specifically Bind CD38
EP3350595B1 (en) * 2015-09-14 2021-08-04 Leukemia Therapeutics, LLC Identification of novel diagnostics and therapeutics by modulating rhoh
MA43187B1 (fr) 2015-11-03 2021-02-26 Janssen Biotech Inc Formulations sous-cutanée d'anticorps anti-cd38 et leurs utilisations
US10781261B2 (en) 2015-11-03 2020-09-22 Janssen Biotech, Inc. Subcutaneous formulations of anti-CD38 antibodies and their uses
WO2019035938A1 (en) 2017-08-16 2019-02-21 Elstar Therapeutics, Inc. MULTISPECIFIC MOLECULES BINDING TO BCMA AND USES THEREOF
US11618787B2 (en) 2017-10-31 2023-04-04 Janssen Biotech, Inc. Methods of treating high risk multiple myeloma
CN113574071A (zh) 2019-03-15 2021-10-29 莫佛塞斯公司 用于治疗自身抗体介导的自身免疫疾病的抗-cd38抗体及其药物组合物
US11655302B2 (en) 2019-06-10 2023-05-23 Sanofi Anti-CD38 antibodies and formulations
CN112876563B (zh) * 2019-11-29 2022-08-16 康诺亚生物医药科技（成都）有限公司 药物组合物及其制备方法和应用
CN115698064A (zh) 2019-12-05 2023-02-03 赛诺菲-安万特美国有限责任公司 用于皮下施用的抗cd38抗体的配制品
WO2022152823A1 (en) 2021-01-14 2022-07-21 Morphosys Ag Anti-cd38 antibodies and their uses
TW202302642A (zh) 2021-03-01 2023-01-16 德商莫菲西斯公司 用於治療抗體介導移植物排斥用途之抗ｃｄ３８抗體
CN113278075B (zh) * 2021-06-18 2021-12-14 芜湖森爱驰生物科技有限公司 一种炎症检测试剂盒
TW202321303A (zh) 2021-07-19 2023-06-01 德商莫菲西斯公司 抗pla2r自體抗體媒介膜性腎病變之治療

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4444887A (en) 1979-12-10 1984-04-24 Sloan-Kettering Institute Process for making human antibody producing B-lymphocytes
US4716111A (en) 1982-08-11 1987-12-29 Trustees Of Boston University Process for producing human antibodies
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
GB8928874D0 (en) 1989-12-21 1990-02-28 Celltech Ltd Humanised antibodies
DE69133566T2 (de) 1990-01-12 2007-12-06 Amgen Fremont Inc. Bildung von xenogenen Antikörpern
US5814318A (en) 1990-08-29 1998-09-29 Genpharm International Inc. Transgenic non-human animals for producing heterologous antibodies
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
DE69233482T2 (de) 1991-05-17 2006-01-12 Merck & Co., Inc. Verfahren zur Verminderung der Immunogenität der variablen Antikörperdomänen
AU675916B2 (en) 1991-06-14 1997-02-27 Genentech Inc. Method for making humanized antibodies
ES2136092T3 (es) 1991-09-23 1999-11-16 Medical Res Council Procedimientos para la produccion de anticuerpos humanizados.
US5639641A (en) 1992-09-09 1997-06-17 Immunogen Inc. Resurfacing of rodent antibodies
ATE390933T1 (de) 1995-04-27 2008-04-15 Amgen Fremont Inc Aus immunisierten xenomäusen stammende menschliche antikörper gegen il-8
AU2466895A (en) 1995-04-28 1996-11-18 Abgenix, Inc. Human antibodies derived from immunized xenomice
US5916771A (en) 1996-10-11 1999-06-29 Abgenix, Inc. Production of a multimeric protein by cell fusion method
AU5702298A (en) 1996-12-03 1998-06-29 Abgenix, Inc. Transgenic mammals having human Ig loci including plural VH and VK regions nd antibodies produced therefrom
SI0970126T1 (en) 1997-04-14 2001-08-31 Micromet Ag Novel method for the production of antihuman antigen receptors and uses thereof
US6235883B1 (en) 1997-05-05 2001-05-22 Abgenix, Inc. Human monoclonal antibodies to epidermal growth factor receptor
WO1999062526A2 (en) * 1998-06-05 1999-12-09 Mayo Foundation For Medical Education And Research Use of genetically engineered antibodies to cd38 to treat multiple myeloma
US20080057070A1 (en) * 2004-11-04 2008-03-06 Chiron Corporation Antagonist Anti-Cd40 Monoclonal Antibodies and Methods for Their Use
CN101218256B (zh) * 2005-03-23 2017-04-19 根马布股份公司 用于治疗多发性骨髓瘤的cd38抗体
US9040050B2 (en) * 2006-09-26 2015-05-26 Genmab A/S Combination treatment of CD38-expressing tumors
EP1914242A1 (en) * 2006-10-19 2008-04-23 Sanofi-Aventis Novel anti-CD38 antibodies for the treatment of cancer
EP2245065A1 (en) * 2008-01-23 2010-11-03 Xencor, Inc. Optimized cd40 antibodies and methods of using the same
EP2191842A1 (en) * 2008-11-28 2010-06-02 Sanofi-Aventis Antitumor combinations containing antibodies recognizing specifically CD38 and cytarabine

Also Published As

Publication number Publication date
LT2370096T (lt) 2017-09-25
AU2009321251B2 (en) 2016-06-09
TW201023863A (en) 2010-07-01
SI2370096T1 (sl) 2017-10-30
HN2011001423A (es) 2014-01-13
JP2015205893A (ja) 2015-11-19
AU2009321251A1 (en) 2010-06-03
BRPI0921858B1 (pt) 2022-11-16
EP2191842A1 (en) 2010-06-02
IL213118A0 (en) 2011-07-31
HRP20171301T1 (hr) 2017-10-20
PL2370096T3 (pl) 2017-10-31
DK2370096T3 (en) 2017-07-17
NZ593085A (en) 2012-12-21
CN102264386A (zh) 2011-11-30
KR20110096551A (ko) 2011-08-30
BRPI0921858A2 (pt) 2018-10-09
RS56248B1 (sr) 2017-11-30
EP2370096A1 (en) 2011-10-05
CA2745005C (en) 2020-08-11
KR101715958B1 (ko) 2017-03-14
UY32266A (es) 2010-06-30
IL213115A0 (en) 2011-07-31
HUE035910T2 (en) 2018-05-28
PA8849901A1 (es) 2010-07-27
US20120093806A1 (en) 2012-04-19
CN107096022A (zh) 2017-08-29
AR073425A1 (es) 2010-11-03
MA32899B1 (fr) 2011-12-01
MX344973B (es) 2017-01-12
IL213115A (en) 2017-08-31
TN2011000242A1 (en) 2012-12-17
CO6440556A2 (es) 2012-05-15
CL2011001232A1 (es) 2012-02-10
PT2370096T (pt) 2017-09-08
SG171821A1 (en) 2011-07-28
ZA201104064B (en) 2012-09-26
EA201100868A1 (ru) 2011-10-31
MX2011005666A (es) 2011-09-30
EP2370096B1 (en) 2017-05-31
TWI436770B (zh) 2014-05-11
NI201100107A (es) 2011-09-26
IL213118A (en) 2017-08-31
CA2745005A1 (en) 2010-06-03
UA104160C2 (uk) 2014-01-10
JP6072854B2 (ja) 2017-02-01
DK2370096T5 (en) 2017-09-18
JP2012510463A (ja) 2012-05-10
WO2010061359A1 (en) 2010-06-03
EA027070B1 (ru) 2017-06-30
ES2638926T3 (es) 2017-10-24
ECSP11011071A (es) 2011-07-29
CR20110282A (es) 2011-09-20

Similar Documents

Publication Publication Date Title
PE20120205A1 (es) Combinaciones antitumorales que contienen anticuerpos que reconocen especificamente cd38 y citarabina
PE20120340A1 (es) Combinaciones antitumorales que contienen anticuerpos que reconocen especificamente cd38 y melfalan
PE20140806A1 (es) Anticuerpos anti-factor d humanizados y sus usos
ES2543174T3 (es) Composición medicinal para el tratamiento y/o la prevención del cáncer
PE20140004A1 (es) Combinaciones antitumorales que contienen anticuerpos que reconocen especificamente cd38 y bortezomib
PE20120902A1 (es) Anticuerpos anti-egfl7 humanizados
PE20141045A1 (es) Proteinas de union a bcma (cd269/tnfrsf17)
PE20121616A1 (es) Anticuerpos anti-her3
PE20140247A1 (es) Anticuerpos anti-cd38
PE20141151A1 (es) Proteinas de union al antigeno cd27l
PE20130817A1 (es) Anticuerpos peptidicos beta amiloide anti-n3pglu y usos de los mismos
PE20131209A1 (es) Anticuerpos anti-fap
PE20140231A1 (es) Proteinas de union a antigeno contra proproteina converstasa subtilisina/kexina tipo 9 (pcsk9)
PE20141162A1 (es) Anticuerpos anti-il-23
PE20080035A1 (es) Anticuerpos monoclonales humanos para la quinasa-1 tipo receptor de activina
ES2687282T3 (es) Anticuerpos humanizados ANTI-CD134 (OX40) y sus usos
PE20140190A1 (es) Moduladores de proteinas notum y metodos de uso
PE20110306A1 (es) Anticuerpos humanos que se unen al gen 3 de activacion linfocitaria (lag-3)
PE20180502A1 (es) Composiciones anti-cgrp y uso de las mismas
PE20140814A1 (es) Anticuerpos contra la angiopoyetina 2 humana
PE20141271A1 (es) Anticuerpos tipo receptor de celulas t especificos para un peptido wt1 presentado por hla-a2
PE20140882A1 (es) Anticuerpos neutralizantes de citomegalovirus humano
PE20130393A1 (es) Anticuerpos con union de antigenos dependiente de ph
ES2689746T3 (es) Anticuerpos monoclonales contra la claudina-18 para el tratamiento de cáncer
PE20121691A1 (es) Formulacion de anticuerpos y regimenes terapeuticos

Legal Events

Date Code Title Description
FC Refusal